Par Drugs & Chemicals Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Reflect Renewed Appeal

As of 10 Aug 2026, Par Drugs & Chemicals Ltd trades at a P/E ratio of 9.24, a substantial moderation from levels that previously labelled it as very expensive. This figure compares favourably against the industry peers, where companies such as J.G. Chemicals and Titan Biotech command P/E ratios of 32.97 and 56.7 respectively. The company’s price-to-book value stands at 1.08, indicating that the stock is priced close to its net asset value, a stark contrast to the premium valuations seen in many of its sector counterparts.

Other valuation multiples further reinforce this narrative. The enterprise value to EBITDA (EV/EBITDA) ratio is 4.63, which is significantly lower than peers like Titan Biotech (43.98) and J.G. Chemicals (24.61). This suggests that Par Drugs & Chemicals is trading at a discount on an operational earnings basis, potentially offering investors a more cost-effective entry point.

Comparative Industry Context

Within the Chemicals & Petrochemicals sector, valuation disparities are pronounced. While some companies such as Gulshan Polyols are rated as attractive with a P/E of 29.69, others like Oriental Aromatics trade at extremely high multiples (P/E of 241.65), reflecting divergent growth expectations and risk profiles. Par Drugs & Chemicals’ current fair valuation grade, supported by a Mojo Score of 51.0 and a recent upgrade from Sell to Hold on 3 Aug 2026, signals a recalibration of market sentiment towards the stock.

Its micro-cap status, however, implies higher volatility and liquidity considerations, which investors should weigh alongside valuation improvements.

Financial Performance and Returns Analysis

Par Drugs & Chemicals’ return profile over various time horizons presents a mixed picture. The stock has delivered a 7.55% return over the past month, outperforming the Sensex’s 0.70% gain in the same period. Year-to-date, the stock is down by 2.82%, though this is less severe than the Sensex’s 5.97% decline, indicating relative resilience amid broader market weakness.

Longer-term returns, however, have been disappointing. Over three years, the stock has declined by 46.52%, significantly underperforming the Sensex’s 25.38% gain. Similarly, the five-year return stands at -17.31%, compared to the Sensex’s robust 51.31% appreciation. These figures underscore the challenges the company has faced historically, which may have contributed to its prior expensive valuation being re-rated downward.

Operational Efficiency and Profitability Metrics

Despite valuation headwinds, Par Drugs & Chemicals demonstrates solid operational metrics. The company’s return on capital employed (ROCE) is a healthy 19.15%, signalling efficient use of capital to generate earnings. Return on equity (ROE) stands at 11.71%, reflecting moderate profitability for shareholders. These figures provide a fundamental underpinning for the stock’s fair valuation and support the recent upgrade in its Mojo Grade from Sell to Hold.

Other valuation multiples such as EV to EBIT (5.90) and EV to Capital Employed (1.13) further indicate that the company is reasonably priced relative to its earnings and asset base, especially when contrasted with more richly valued peers.

Price Movement and Market Capitalisation

On 10 Aug 2026, Par Drugs & Chemicals closed at ₹98.40, down 2.50% from the previous close of ₹100.92. The stock’s 52-week high and low stand at ₹122.43 and ₹78.05 respectively, indicating a moderate trading range. The company’s micro-cap status suggests limited market capitalisation, which can lead to higher price volatility and less analyst coverage, factors that investors should consider when evaluating the stock’s risk-reward profile.

Peer Comparison Highlights

When benchmarked against its peers, Par Drugs & Chemicals’ valuation multiples stand out for their relative conservatism. For instance, Titan Biotech’s P/E ratio of 56.7 and EV/EBITDA of 43.98 reflect expectations of strong growth or superior profitability, but also imply higher risk and premium pricing. Similarly, Indo Borax & Chemicals trades at a P/E of 30.06 and EV/EBITDA of 24.41, underscoring the wide valuation dispersion within the sector.

In contrast, Par Drugs & Chemicals’ PEG ratio is reported as 0.00, which may indicate either a lack of meaningful earnings growth or data unavailability, but also suggests the stock is not priced for growth, aligning with its fair valuation status. This conservative valuation could appeal to value-oriented investors seeking exposure to the chemicals sector without paying a premium.

Outlook and Investment Considerations

The recent upgrade in Mojo Grade from Sell to Hold, accompanied by a valuation grade shift from very expensive to fair, signals a positive change in market perception. Investors should note that while the stock’s valuation metrics have improved, the company’s long-term return track record remains subdued relative to the broader market.

Given its micro-cap classification, Par Drugs & Chemicals may offer opportunities for investors willing to accept higher volatility in exchange for potential upside from valuation rerating. The company’s solid ROCE and ROE metrics provide a fundamental base, but prospective investors should monitor earnings growth and sector dynamics closely.

Overall, the stock’s current price attractiveness, supported by a P/E of 9.24 and P/BV near book value, makes it a candidate for consideration within a diversified portfolio, particularly for those seeking exposure to the Chemicals & Petrochemicals sector at reasonable valuations.

Summary

Par Drugs & Chemicals Ltd’s valuation transformation from very expensive to fair, combined with its operational efficiency and recent Mojo Grade upgrade, marks a noteworthy development for investors. While the stock’s historical returns have lagged the Sensex, its improved price multiples relative to peers and solid profitability metrics suggest a more balanced risk-reward profile going forward. Careful monitoring of market conditions and company fundamentals will be essential to assess whether this valuation shift translates into sustained share price appreciation.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →